Klaus Veitinger

Klaus Veitinger is currently a Venture Partner with OrbiMed and he served as Chairman of Promentis Pharmaceuticals from April 2008 until February 2014. During his prior 16-year pharmaceutical career, Klaus Veitinger held senior management positions in drug development, licensing and business development, strategic planning and M&A, as well as general management. Most recently Klaus Veitinger was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma Inc. with responsibility for the U.S. and Asia businesses culminating in the ultimate sale of the Schwarz Group. Klaus Veitinger has served and currently serves on the boards of several private and public companies in the life sciences sector. For seven years he was a Director of PhRMA. Klaus Veitinger received his medical degree and his doctorate (Ph.D.) from the University of Heidelberg. He earned his M.B.A. at INSEAD in France.